Present knowledge shows that lifelong IGF1 deficiency in untreated patients with LS does not seem to markedly influence their lifespan, unless they neglect to treat in time the metabolic and cardiovascular complications of this condition, such as diabetes mellitus and hyperlipidemia. Here, IGF1 is linked to hyperlipidemia.